Abstract
Abiraterone acetate (AA) is a CYP17 inhibitor of androgen synthesis approved for use following docetaxel for metastatic castration-resistant prostate cancer (mCRPC); evaluation in the pre-docetaxel setting is ongoing. Given that the reported efficacy of AA is lower following docetaxel vs. pre-docetaxel, the potential exists for cross resistance given docetaxel's partly androgen receptor targeting activity. The efficacy of docetaxel following ketoconazole (KC), a weaker and nonspecific inhibitor of CYP17, may provide some insights into this potential interaction. We retrospectively evaluated the efficacy of every 3-week docetaxel with prednisone (DP) in mCRPC previously exposed to KC compared to KC-naive patients. A randomized phase II trial of men with mCRPC treated with DP + AT-101 (bcl-2 inhibitor) vs. DP plus placebo was analyzed. Both arms were combined for analysis as no significant differences were seen. Overall survival (OS), progression-free survival (PFS), objective response (ORR), pain, and prostate-specific antigen (PSA) response rates were estimated with and without prior KC. Cox proportional hazards regression models were used to estimate the effect of covariates on OS. Of 220 evaluable men, 40 (18.2%) received pri...Continue Reading
References
Oct 19, 2001·Endocrinology·H MurilloD J Tindall
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·M MercaderE D Kwon
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallNicholas J Vogelzang
Mar 16, 2005·Cancer Cell·Charles G DrakeAdam J Adler
Oct 4, 2006·The Journal of Clinical Investigation·Michael R MancusoDonald M McDonald
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew J ArmstrongMario Eisenberger
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Mar 3, 2009·Cancer Cell·Marta Pàez-RibesOriol Casanovas
Mar 3, 2009·Cancer Cell·John M L EbosRobert S Kerbel
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhardt AttardJohann S de Bono
Oct 15, 2009·Cancer Research·Lu GanHaojie Huang
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C DanilaHoward I Scher
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J RyanEric J Small
Jun 16, 2010·Cancer·Robert J MotzerUNKNOWN RECORD‐1 Study Group
Sep 3, 2010·Cancer Research·Meng-Lei ZhuNatasha Kyprianou
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 5, 2010·Lancet·Johann Sebastian de BonoUNKNOWN TROPIC Investigators
Feb 16, 2011·Proceedings of the National Academy of Sciences of the United States of America·Olivier KeunenSimone P Niclou
Mar 1, 2011·Lancet·Karim FizaziCarsten Goessl
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elahe A MostaghelR Bruce Montgomery
Sep 1, 2011·European Urology·Jerome P Richie
Citations
Jan 18, 2014·Asian Journal of Andrology·Michael T Schweizer, Emmanuel S Antonarakis
May 3, 2014·Clinical Genitourinary Cancer·Rahul AggarwalCharles J Ryan
Jul 30, 2014·Clinical Genitourinary Cancer·Avishay SellaDaniel Keizman
Feb 5, 2014·European Urology·Michael T SchweizerEmmanuel S Antonarakis
May 27, 2014·American Society of Clinical Oncology Educational Book·Cora N SternbergChris Parker
Aug 30, 2018·Nature Reviews. Urology·Vaibhav PatelWilliam Oh
Nov 16, 2016·F1000Research·Mehrad MahmoudianLaura L Elo
Dec 28, 2019·Cancers·Sirin SaranyutanonAjay Pratap Singh